MacroGenics, Inc. (MGNX) Stake Raised by Citadel Advisors LLC

Citadel Advisors LLC boosted its position in MacroGenics, Inc. (NASDAQ:MGNX) by 55.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 85,927 shares of the biopharmaceutical company’s stock after acquiring an additional 30,594 shares during the period. Citadel Advisors LLC owned 0.23% of MacroGenics worth $1,588,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in MGNX. Russell Investments Group Ltd. bought a new stake in MacroGenics in the 2nd quarter valued at about $133,000. Legal & General Group Plc raised its stake in MacroGenics by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 328 shares during the period. SG Americas Securities LLC raised its stake in MacroGenics by 92.2% in the 2nd quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 5,187 shares during the period. Parametric Portfolio Associates LLC bought a new stake in MacroGenics in the 2nd quarter valued at about $203,000. Finally, Virtu KCG Holdings LLC bought a new stake in MacroGenics in the 2nd quarter valued at about $232,000. Institutional investors and hedge funds own 85.81% of the company’s stock.

MacroGenics, Inc. (NASDAQ MGNX) opened at $19.05 on Thursday. MacroGenics, Inc. has a twelve month low of $14.36 and a twelve month high of $28.48.

MacroGenics (NASDAQ:MGNX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $5.50 million. MacroGenics had a negative net margin of 1,526.55% and a negative return on equity of 69.31%. The firm’s quarterly revenue was down 48.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.97) EPS. research analysts forecast that MacroGenics, Inc. will post -0.7 EPS for the current year.

A number of equities research analysts recently issued reports on the company. ValuEngine upgraded MacroGenics from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. Citigroup boosted their price objective on MacroGenics from $18.00 to $22.00 and gave the company a “neutral” rating in a research note on Friday, November 10th. Cowen restated a “buy” rating on shares of MacroGenics in a research note on Wednesday, October 25th. Zacks Investment Research upgraded MacroGenics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $34.00 price objective on shares of MacroGenics in a research note on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $30.10.

In other MacroGenics news, SVP Jon Marc Wigginton sold 5,000 shares of MacroGenics stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the transaction, the senior vice president now owns 35,000 shares of the company’s stock, valued at approximately $700,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 8.30% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “MacroGenics, Inc. (MGNX) Stake Raised by Citadel Advisors LLC” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/07/macrogenics-inc-mgnx-stake-raised-by-citadel-advisors-llc.html.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics, Inc. (NASDAQ:MGNX).

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

What are top analysts saying about MacroGenics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MacroGenics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit